PRQR Stock Analysis: Buy, Sell, or Hold?
PRQR - ProQR Therapeutics N.V. Ordinary Shares
$1.76
0.05 (2.92%)
▲
5d:
+28.47%
30d:
+4.14%
90d:
-11.56%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
PRQR is down 5.0% this week, but smart money is accumulating calls. Top strike: $2.5 2026-04-17 with 2,811 OI. Call ratio: 100% View Scanner →
Strength: 7.5/10
Get Alerted When PRQR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PRQR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PRQR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PRQR is currently trading at $1.76, which is considered extended relative to its 30-day fair value range of $1.53 to $1.78.
Technical Outlook: Technically, PRQR is in a strong downtrend. Immediate support is located at $1.35, while resistance sits at $1.86.
Market Sentiment: PRQR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.88 (+419.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRQR is in a strong downtrend. Immediate support is located at $1.35, while resistance sits at $1.86.
Market Sentiment: PRQR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.88 (+419.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$1.53 -
$1.78
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 419.0% below Wall St target ($8.88)
Fair Price Analysis
30-Day Fair Range
$1.53 -
$1.78
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$1.35
Resistance Level
$1.86
Current Trend
Strong Downtrend
Technical data as of
Apr 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.43
Wall Street Target
$8.88
(+419.0%)
Revenue Growth (YoY)
6.1%
Profit Margin
-258.0%
Share & Embed Analysis
Last updated: April 06, 2026 1:10 PM ET
Data refreshes hourly during market hours. Next update: 2:10 PM
Data refreshes hourly during market hours. Next update: 2:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRQR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$50 | 54 HOLD |
